[Systemic therapy for advanced endometrial cancer].

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Cancer Therapeutics

Background:

• Endometrial cancer typically has a good prognosis when diagnosed early.
• Advanced stages (recurrent or metastatic) present therapeutic challenges with limited options.
• Understanding tumor biology is crucial for developing effective treatments.

Purpose of the Study:

• To review current therapeutic options for advanced endometrial cancer.
• To highlight the role of hormonal therapy, chemotherapy, and emerging targeted therapies.
• To emphasize the importance of personalized treatment based on tumor characteristics and patient comorbidities.

Main Methods:

• Review of current literature on endometrial cancer treatment strategies.
• Analysis of efficacy and toxicity profiles of different therapeutic modalities.
• Discussion of factors influencing treatment selection, including tumor histology and patient status.

Main Results:

• Hormonal therapy is effective for slow-progressing, hormone receptor-positive tumors due to its safety.
• Combination chemotherapy (taxanes, anthracyclines, platinum compounds) shows higher response rates but increased toxicity.
• Targeted therapies are under evaluation and show promising results in preclinical and clinical studies.

Conclusions:

• Personalized treatment decisions for advanced endometrial cancer require comprehensive knowledge of patient comorbidities and precise tumor characteristics (type, grade, receptor status, MSI status).
• While established therapies like hormonal therapy and chemotherapy remain important, targeted therapies represent a growing area with potential to improve outcomes.
• Further research into novel therapeutic strategies is essential for managing advanced endometrial cancer effectively.